Envestnet Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$242M Sell
487,627
-15,937
-3% -$7.06M 0.06% 305
2026
Q1
$225M Buy
503,564
+31,921
+7% +$14.9M 0.06% 292
2025
Q4
$214M Buy
471,643
+888
+0.2% +$383K 0.06% 286
2025
Q3
$184M Buy
470,755
+21,767
+5% +$9.1M 0.05% 338
2025
Q2
$200M Sell
448,988
-21,340
-5% -$9.83M 0.06% 307
2025
Q1
$228M Buy
470,328
+47,630
+11% +$22.2M 0.07% 262
2024
Q4
$170M Buy
422,698
+19,630
+5% +$9.1M 0.05% 325
2024
Q3
$187M Sell
403,068
-11,992
-3% -$5.76M 0.06% 293
2024
Q2
$195M Buy
415,060
+11,751
+3% +$5.1M 0.07% 261
2024
Q1
$169M Sell
403,309
-9,320
-2% -$3.94M 0.06% 290
2023
Q4
$168M Buy
412,629
+1,143
+0.3% +$422K 0.07% 280
2023
Q3
$143M Buy
411,486
+105,232
+34% +$36.8M 0.07% 286
2023
Q2
$108M Sell
306,254
-1,145,620
-79% -$386M 0.05% 322
2023
Q1
$92.7M Buy
1,451,874
+1,167,674
+411% +$350M 0.04% 346
2022
Q4
$82.1M Buy
284,200
+14,768
+5% +$4.5M 0.04% 359
2022
Q3
$78M Buy
269,432
+13,885
+5% +$3.99M 0.04% 339
2022
Q2
$72M Sell
255,547
-52,192
-17% -$14M 0.04% 353
2022
Q1
$80.3M Buy
307,739
+38,499
+14% +$9.14M 0.04% 357
2021
Q4
$59.1M Buy
269,240
+20,854
+8% +$4.06M 0.03% 438
2021
Q3
$45.1M Buy
248,386
+53,642
+28% +$10.5M 0.02% 489
2021
Q2
$39.3M Sell
194,744
-13,933
-7% -$2.91M 0.02% 525
2021
Q1
$44.8M Buy
208,677
+19,743
+10% +$4.34M 0.03% 440
2020
Q4
$44.7M Sell
188,934
-108
-0.1% -$24.8K 0.03% 380
2020
Q3
$51.4M Buy
189,042
+25,601
+16% +$7.06M 0.05% 298
2020
Q2
$47.4M Buy
163,441
+49,186
+43% +$13.3M 0.05% 295
2020
Q1
$27.2M Buy
114,255
+20,284
+22% +$4.65M 0.03% 367
2019
Q4
$20.6M Buy
93,971
+6,621
+8% +$1.34M 0.02% 522
2019
Q3
$14.8M Buy
87,350
+3,372
+4% +$597K 0.02% 585
2019
Q2
$15.4M Buy
83,978
+3,297
+4% +$576K 0.02% 564
2019
Q1
$14.8M Buy
80,681
+9,146
+13% +$1.69M 0.02% 542
2018
Q4
$11.9M Buy
71,535
+58,803
+462% +$10.2M 0.02% 544
2018
Q3
$2.45M Sell
12,732
-13,821
-52% -$2.46M ﹤0.01% 568
2018
Q2
$4.51M Buy
26,553
+8,887
+50% +$1.38M 0.01% 524
2018
Q1
$2.88M Sell
17,666
-15,954
-47% -$2.61M 0.01% 574
2017
Q4
$5.04M Buy
33,620
+1,373
+4% +$203K 0.01% 594
2017
Q3
$4.9M Buy
32,247
+8,088
+33% +$1.22M 0.01% 560
2017
Q2
$3.11M Buy
24,159
+5,525
+30% +$665K 0.01% 754
2017
Q1
$2.04M Buy
18,634
+3,597
+24% +$317K 0.01% 928
2016
Q4
$1.11M Sell
15,037
-2,668
-15% -$217K ﹤0.01% 1143
2016
Q3
$1.54M Sell
17,705
-9,276
-34% -$877K 0.01% 1053
2016
Q2
$2.32M Sell
26,981
-2,069
-7% -$179K 0.01% 950
2016
Q1
$2.31M Sell
29,050
-1,997
-6% -$181K 0.01% 915
2015
Q4
$3.91M Sell
31,047
-3,653
-11% -$441K 0.02% 677
2015
Q3
$3.61M Buy
34,700
+2,553
+8% +$328K 0.02% 697
2015
Q2
$3.97M Buy
32,147
+1,895
+6% +$239K 0.02% 715
2015
Q1
$3.57M Buy
30,252
+30,062
+15,822% +$3.6M 0.02% 712
2014
Q4
$23K Buy
190
+12
+7% +$1.35K ﹤0.01% 1695
2014
Q3
$20K Buy
178
+83
+87% +$7.9K ﹤0.01% 1889
2014
Q2
$9K Sell
95
-61
-39% -$4.28K ﹤0.01% 2102
2014
Q1
$11K Sell
156
-48
-24% -$3.8K ﹤0.01% 1854
2013
Q4
$15K Sell
204
-400
-66% -$27.9K ﹤0.01% 1602
2013
Q3
$46K Buy
604
+10
+2% +$796 ﹤0.01% 1221
2013
Q2
$48K Buy
+594
New +$43.7K ﹤0.01% 1179

Other funds holding VRTX

Envestnet Asset Management's VRTX Position: Q2 2026 in Review

Envestnet Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q2 2026, selling an estimated $7.06M and leaving 487,627 shares worth $242M. The position accounts for 0.06% of the portfolio, ranked #305.

Envestnet Asset Management first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Envestnet Asset Management held 487,627 shares of Vertex Pharmaceuticals worth $242M as of Q2 2026.
  • Envestnet Asset Management sold 15,937 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.06M.
  • Vertex Pharmaceuticals made up 0.06% of Envestnet Asset Management's portfolio in Q2 2026, its #305 holding.
  • Envestnet Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.